FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3176702900> ?p ?o ?g. }

• W3176702900 abstract "ABSTRACT Effective therapeutics to inhibit the replication of SARS-CoV-2 in infected individuals are still under development. The nucleoside analogue N4-hydroxycytidine (NHC), also known as EIDD-1931, interferes with SARS-CoV-2 replication in cell culture. It is the active metabolite of the prodrug Molnupiravir (MK-4482), which is currently being evaluated for the treatment of COVID-19 in advanced clinical studies. Meanwhile, inhibitors of dihydroorotate dehydrogenase (DHODH), by reducing the cellular synthesis of pyrimidines, counteract virus replication and are also being clinically evaluated for COVID-19 therapy. Here we show that the combination of NHC and DHODH inhibitors such as teriflunomide, IMU-838/vidofludimus, and BAY2402234, strongly synergizes to inhibit SARS-CoV-2 replication. While single drug treatment only mildly impaired virus replication, combination treatments reduced virus yields by at least two orders of magnitude. We determined this by RT-PCR, TCID 50 , immunoblot and immunofluorescence assays in Vero E6 and Calu-3 cells infected with wildtype and the Alpha and Beta variants of SARS-CoV-2. We propose that the lack of available pyrimidine nucleotides upon DHODH inhibition increases the incorporation of NHC in nascent viral RNA, thus precluding the correct synthesis of the viral genome in subsequent rounds of replication, thereby inhibiting the production of replication competent virus particles. This concept was further supported by the rescue of replicating virus after addition of pyrimidine nucleosides to the media. Based on our results, we suggest combining these drug candidates, which are currently both tested in clinical studies, to counteract the replication of SARS-CoV-2, the progression of COVID-19, and the transmission of the disease within the population. SIGNIFICANCE The strong synergy displayed by DHODH inhibitors and the active compound of Molnupiravir might enable lower concentrations of each drug to antagonize virus replication, with less toxicity. Both Molnupiravir and DHODH inhibitors are currently being tested in advanced clinical trials or are FDA-approved for different purposes, raising the perspective of rapidly testing their combinatory efficacy in clinical studies. Molnupiravir is currently a promising candidate for treating early stages of COVID-19, under phase II/III clinical evaluation. However, like Remdesivir, it appears only moderately useful in treating severe COVID-19. Since the combination inhibits virus replication far more strongly, and since DHODH inhibitors may also suppress excessive immune responses, the combined clinical application bears the potential of alleviating the disease burden even at later stages." @default.
• W3176702900 created "2021-07-05" @default.
• W3176702900 creator A5004540529 @default.
• W3176702900 creator A5033345296 @default.
• W3176702900 creator A5049218335 @default.
• W3176702900 creator A5050213096 @default.
• W3176702900 creator A5057181204 @default.
• W3176702900 creator A5073546944 @default.
• W3176702900 creator A5077281354 @default.
• W3176702900 date "2021-06-28" @default.
• W3176702900 modified "2023-09-24" @default.
• W3176702900 title "N4-hydroxycytidine and inhibitors of dihydroorotate dehydrogenase synergistically suppress SARS-CoV-2 replication" @default.
• W3176702900 cites W1515293536 @default.
• W3176702900 cites W1970487533 @default.
• W3176702900 cites W1974756544 @default.
• W3176702900 cites W1975772219 @default.
• W3176702900 cites W1979012760 @default.
• W3176702900 cites W2009987166 @default.
• W3176702900 cites W2012457782 @default.
• W3176702900 cites W2027535855 @default.
• W3176702900 cites W2034082255 @default.
• W3176702900 cites W2045074917 @default.
• W3176702900 cites W2050674793 @default.
• W3176702900 cites W2069445877 @default.
• W3176702900 cites W2078627161 @default.
• W3176702900 cites W2092911406 @default.
• W3176702900 cites W2096439168 @default.
• W3176702900 cites W2120649647 @default.
• W3176702900 cites W2125462233 @default.
• W3176702900 cites W2139086828 @default.
• W3176702900 cites W2166483999 @default.
• W3176702900 cites W2189487392 @default.
• W3176702900 cites W2312482418 @default.
• W3176702900 cites W2481374159 @default.
• W3176702900 cites W2582590404 @default.
• W3176702900 cites W2594626196 @default.
• W3176702900 cites W2595347511 @default.
• W3176702900 cites W2756294165 @default.
• W3176702900 cites W2770157223 @default.
• W3176702900 cites W2807193652 @default.
• W3176702900 cites W2945440984 @default.
• W3176702900 cites W2979108578 @default.
• W3176702900 cites W2981723136 @default.
• W3176702900 cites W2996962570 @default.
• W3176702900 cites W3001195213 @default.
• W3176702900 cites W3014708904 @default.
• W3176702900 cites W3027630905 @default.
• W3176702900 cites W3032677067 @default.
• W3176702900 cites W3047125225 @default.
• W3176702900 cites W3082108964 @default.
• W3176702900 cites W3085591857 @default.
• W3176702900 cites W3089675328 @default.
• W3176702900 cites W3092867631 @default.
• W3176702900 cites W3108974439 @default.
• W3176702900 cites W3109110891 @default.
• W3176702900 cites W3110209099 @default.
• W3176702900 cites W3112281188 @default.
• W3176702900 cites W3112902030 @default.
• W3176702900 cites W3113068658 @default.
• W3176702900 cites W3119415300 @default.
• W3176702900 cites W3126546961 @default.
• W3176702900 cites W3135383916 @default.
• W3176702900 cites W3139503800 @default.
• W3176702900 cites W3172520795 @default.
• W3176702900 cites W4210642183 @default.
• W3176702900 cites W4211183388 @default.
• W3176702900 doi "https://doi.org/10.1101/2021.06.28.450163" @default.
• W3176702900 hasPublicationYear "2021" @default.
• W3176702900 type Work @default.
• W3176702900 sameAs 3176702900 @default.
• W3176702900 citedByCount "1" @default.
• W3176702900 countsByYear W31767029002021 @default.
• W3176702900 crossrefType "posted-content" @default.
• W3176702900 hasAuthorship W3176702900A5004540529 @default.
• W3176702900 hasAuthorship W3176702900A5033345296 @default.
• W3176702900 hasAuthorship W3176702900A5049218335 @default.
• W3176702900 hasAuthorship W3176702900A5050213096 @default.
• W3176702900 hasAuthorship W3176702900A5057181204 @default.
• W3176702900 hasAuthorship W3176702900A5073546944 @default.
• W3176702900 hasAuthorship W3176702900A5077281354 @default.
• W3176702900 hasBestOaLocation W31767029001 @default.
• W3176702900 hasConcept C108215921 @default.
• W3176702900 hasConcept C140704245 @default.
• W3176702900 hasConcept C159047783 @default.
• W3176702900 hasConcept C181199279 @default.
• W3176702900 hasConcept C200159599 @default.
• W3176702900 hasConcept C203014093 @default.
• W3176702900 hasConcept C2522874641 @default.
• W3176702900 hasConcept C2776036978 @default.
• W3176702900 hasConcept C2776476023 @default.
• W3176702900 hasConcept C2776543447 @default.
• W3176702900 hasConcept C2777333352 @default.
• W3176702900 hasConcept C2777703276 @default.
• W3176702900 hasConcept C2779865431 @default.
• W3176702900 hasConcept C2780640218 @default.
• W3176702900 hasConcept C55493867 @default.
• W3176702900 hasConcept C86803240 @default.
• W3176702900 hasConceptScore W3176702900C108215921 @default.
• W3176702900 hasConceptScore W3176702900C140704245 @default.
• W3176702900 hasConceptScore W3176702900C159047783 @default.

• next